The global law firm Jones Day has announced that two new lawyers have joined the Firm’s office in Shanghai as of counsel. Ross Keene joins the Firm’s Mergers & Acquisitions Practiceand Dr. Yang Xu joins the Intellectual Property Practice. Mr. Keene arrives from the Shanghai office of Allens, where he was Chief Representative, and Dr. Xu arrives from Simcere Pharmaceutical Group, where he was Chief Patent Counsel.
“We are excited to welcome Yang and Ross to Jones Day’s Shanghai Office,” said Peter Wang, Partner-in-Charge of Jones Day Shanghai.”Yang’s patent experience in the pharmaceutical industry will be of immense value to our clients with opportunities in these areas, and Ross’ experience with cross-border transactions — both inbound and outbound – add depth to our transactional capabilities around the world. Their substantial experience, track record, and industry knowledge bring great value to our corporate and life sciences practices in the region.”
Mr. Keene’s practice focuses on cross-border mergers and acquisitions, foreign direct investment, and commercial transactions in China. He has been based in China for more than seven years and represents clients in a number of sectors including energy and resources, financial services, life sciences, telecommunications, media and technology, consumer products, real estate, and manufacturing, with experience that spans the United States and Canada, Europe, Asia, and Australia. Mr. Keene also advises major Chinese state-owned and private companies on their overseas acquisitions and other investment projects in Australia and other parts of the Asia-Pacific region. In addition, he has extensive experience negotiating transaction documents in English and Chinese. Mr. Keene earned his B.A. and LL.B., both with honors, from University of Melbourne.
Dr. Xu’s practice focuses on patent litigation and prosecution, R&D collaboration and licensing, and IP counseling. He has more than a decade of diverse IP experience in patent procurement, patent litigation, patent strategy, IP licensing, IP due diligence, and trade secret protection. As Chief Patent Counsel for Simcere Pharmaceutical Group, he built and led its IP department and played a key role in IP protection and R&D collaborations with international and domestic pharmaceutical companies in the fields of small molecule drugs and biologics. Before moving to China, Dr. Xu practiced law in the United States and represented clients in industry and academia in patent prosecution, licensing, patent strategy, and IP due diligence. Dr. Xu earned a B.S. In Biochemistry from Beijing University, his J.D. from The University of Texas at Austin, and his Ph.D. in Biochemistry and Molecular Biology from The University of Chicago.
Related Posts:
- None Found